Fatty Acid Metabolism in Schizophrenia Treatment

Schizophrenia is increasingly understood as a disorder in which disturbances of lipid biology and inflammatory pathways converge. Brain tissue is rich in phospholipid membranes, within which polyunsaturated fatty acids (PUFAs) such as docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) play critical roles in synaptic function, neurotransmitter release and membrane fluidity. Deficits in these long-chain PUFAs have been linked to both positive and negative symptoms of psychosis, cognitive impairment and altered neurodevelopmental trajectories. Modulating fatty acid metabolism through dietary supplementation or adjunctive pharmacotherapy aims to restore membrane integrity, attenuate neuroinflammation and influence signalling cascades implicated in neural plasticity. Clinical and preclinical studies suggest that timing of intervention—especially during prodromal or early phases—may determine the magnitude of benefit. A convergent body of work has therefore explored fatty acid supplementation alone or in combination with anti-inflammatory agents, yielding insights into mechanisms of action, optimal dosing regimens and patient subgroups most likely to respond.

Research from Nature Portfolio

A long-term follow-up of a randomised, placebo-controlled trial demonstrated that a brief intervention with omega-3 PUFAs in young individuals at subthreshold risk for psychosis reduced the progression to full-blown disorder and improved functional outcomes over a median of 6.7 years. Participants receiving a 12-week course of EPA and DHA showed lower rates of transition to psychotic illness, fewer attenuated symptoms and less overall psychiatric morbidity compared with placebo. These findings support a durable preventive effect of early supplementation on both psychosis risk and broader mental health trajectories.

Fatty Acid Metabolism in Schizophrenia Treatment publication trend

The graph below shows the total number of articles in fatty acid metabolism in schizophrenia treatment across all publications each year (not limited to Nature Index journals).

Technical terms

Polyunsaturated fatty acid (PUFA): Fatty acids containing two or more double bonds, essential for cell membrane structure and signalling.

Omega-3 fatty acids: A subclass of PUFAs (including DHA and EPA) known for anti-inflammatory and neuroprotective properties.

Membrane phospholipids: Lipid molecules forming the bilayer of cell membranes, in which fatty acids regulate fluidity and receptor function.

Neuroinflammation: Activation of immune processes within the brain that can alter neuronal connectivity and neurotransmission.

At-risk mental state (ARMS): A clinical designation for individuals showing early signs of psychosis, before full diagnostic criteria are met.

References

1. Longitudinal Trajectories of Plasma Polyunsaturated Fatty Acids and Associations With Psychosis Spectrum Outcomes in Early Adulthood. Biological Psychiatry (2024).
2. A randomised double-blind placebo-controlled trial of minocycline and/or omega-3 fatty acids added to treatment as usual for at risk Mental States: The NAYAB study. Brain Behavior and Immunity (2023).
3. Supplement Treatment with NAC and Omega-3 Polyunsaturated Fatty Acids during Pregnancy Partially Prevents Schizophrenia-Related Outcomes in the Poly I:C Rat Model. Antioxidants (2023).
4. Longer-term outcome in the prevention of psychotic disorders by the Vienna omega-3 study. Nature Communications (2015).